EVMN Strangle Strategy
EVMN (Evommune, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NYSE.
Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. It develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its products includes EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of AD and UC. The company was incorporated in 2020 and is based in Palo Alto, California.
EVMN (Evommune, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $329.9M, a beta of 0.30 versus the broader market, a 52-week range of 13.885-33.2, average daily share volume of 360K, a public-listing history dating back to 2025, approximately 45 full-time employees. These structural characteristics shape how EVMN stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 0.30 indicates EVMN has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure.
What is a strangle on EVMN?
A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.
Current EVMN snapshot
As of May 15, 2026, spot at $22.75, ATM IV 119.20%, expected move 34.17%. The strangle on EVMN below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.
Why this strangle structure on EVMN specifically: IV rank is unavailable in the current snapshot, so regime-based timing for EVMN is inferred from ATM IV at 119.20% alone, with a market-implied 1-standard-deviation move of approximately 34.17% (roughly $7.77 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated EVMN expiries trade a higher absolute premium for lower per-day decay. Position sizing on EVMN should anchor to the underlying notional of $22.75 per share and to the trader's directional view on EVMN stock.
EVMN strangle setup
The EVMN strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With EVMN near $22.75, the first option leg uses a $23.89 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed EVMN chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 EVMN shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $23.89 | N/A |
| Buy 1 | Put | $21.61 | N/A |
EVMN strangle risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.
EVMN strangle payoff curve
Modeled P&L at expiration across a range of underlying prices for the strangle on EVMN. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use strangle on EVMN
Strangles on EVMN are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the EVMN chain.
EVMN thesis for this strangle
The market-implied 1-standard-deviation range for EVMN extends from approximately $14.98 on the downside to $30.52 on the upside. A EVMN long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. As a Healthcare name, EVMN options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to EVMN-specific events.
EVMN strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. EVMN positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move EVMN alongside the broader basket even when EVMN-specific fundamentals are unchanged. Always rebuild the position from current EVMN chain quotes before placing a trade.
Frequently asked questions
- What is a strangle on EVMN?
- A strangle on EVMN is the strangle strategy applied to EVMN (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With EVMN stock trading near $22.75, the strikes shown on this page are snapped to the nearest listed EVMN chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are EVMN strangle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the EVMN strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 119.20%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a EVMN strangle?
- The breakeven for the EVMN strangle priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current EVMN market-implied 1-standard-deviation expected move is approximately 34.17%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a strangle on EVMN?
- Strangles on EVMN are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the EVMN chain.
- How does current EVMN implied volatility affect this strangle?
- Current EVMN ATM IV is 119.20%; IV rank context is unavailable in the current snapshot.